Previous 10 | Next 10 |
home / stock / crsp / crsp articles
On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO) units....
ZUG, Switzerland and BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creatin...
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 2.15% on an annualized basis producing an average annual ret...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 years ...
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 3.11% on an annualized basis producing an average annual ret...
Monday, CRISPR Therapeutics AG (NASDAQ: CRSP) provided an update on its immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic ch...
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would not buy CRISPR Therapeutics AG (NASDAQ: CRSP) stock "all the...
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Monday on what appears to be continued momentum from the recent regulatory aut...
News, Short Squeeze, Breakout and More Instantly...
CRISPR Therapeutics AG Company Name:
CRSP Stock Symbol:
NASDAQ Market:
CRISPR Therapeutics AG Website:
2024-07-17 10:10:00 ET July 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compan...